PBH
$62.30
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates...
Recent News
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)’s Quarterly Revenue
Prestige Consumer Healthcare Inc. (NYSE:PBH) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Prestige Consumer Healthcare Inc. (NYSE:PBH) stands fifteenth on our list of best healthcare stocks. TheFly reported on February 6 that Canaccord reduced its price target on PBH to $86 from $88 and maintained a Buy rating on the shares. The change came after the company […]
PBH's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Up
Prestige Consumer stock ticks higher as Q3 revenues top estimates, but EPS slips 7% and misses forecasts despite margin expansion.
Prestige Consumer Healthcare (PBH) Valuation Check After Clear Eyes Supply Headwinds And Pillar5 Acquisition
Prestige Consumer Healthcare (PBH) is back in focus after its third quarter results, which combined softer Clear Eyes supply, an earnings miss versus Wall Street, and a slightly narrowed full year revenue outlook around US$1.1b. See our latest analysis for Prestige Consumer Healthcare. The third quarter update, including softer Clear Eyes volumes, an earnings miss and a tighter revenue outlook, comes after a period where the share price has shown short term momentum, with a 30 day share price...
Prestige Consumer Healthcare Q3 Earnings Call Highlights
Prestige Consumer Healthcare (NYSE:PBH) executives told investors the company delivered “solid” fiscal third-quarter results amid what management described as a highly volatile consumer and retail environment, while continuing to work through supply constraints in its Clear Eyes brand. On the compan
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.